

**Glenmark Pharmaceuticals Inc., USA to launch  
Potassium Phosphates Injection USP, 15 mmol P / 22 mEq K per 5 mL  
and 45 mmol P / 66 mEq K per 15 mL Single-Dose Vials  
and 150 mmol P / 220 mEq K per 50 mL Pharmacy Bulk Package Vials**

**Elmwood Park, New Jersey, March 16, 2026** – Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce the upcoming launch<sup>1</sup> of Potassium Phosphates Injection USP, 15 mmol P / 22 mEq K per 5 mL and 45 mmol P / 66 mEq K per 15 mL Single-Dose Vials and 150 mmol P / 220 mEq K per 50 mL Pharmacy Bulk Package Vials. Glenmark's Potassium Phosphates Injection USP, 15 mmol P / 22 mEq K per 5 mL and 45 mmol P / 66 mEq K per 15 mL Single-Dose Vials and 150 mmol P / 220 mEq K per 50 mL Pharmacy Bulk Package Vials is bioequivalent and therapeutically equivalent to the reference listed drug, Potassium Phosphates Injection USP, 15 mmol P / 22 mEq K per 5 mL, 45 mmol P / 66 mEq K per 15 mL, and 150 mmol P / 220 mEq K per 50 mL of Fresenius Kabi [NDA 212832]. Glenmark will begin distribution in March 2026.

According to IQVIA® sales data for the 12-month period ending January 2026, the Potassium Phosphates Injection USP, 15 mmol P / 22 mEq K per 5 mL, 45 mmol P / 66 mEq K per 15 mL, and 150 mmol P / 220 mEq K per 50 mL market<sup>2</sup> achieved annual sales of approximately \$50.7 million\*.

**Commenting on the launch, Marc Kikuchi, President & Business Head, North America said,** “We look forward to growing our portfolio of products within the institutional channel with the upcoming launch of Potassium Phosphates Injection USP, 15 mmol P / 22 mEq K per 5 mL and 45 mmol P / 66 mEq K per 15 mL Single-Dose Vials and 150 mmol P / 220 mEq K per 50 mL Pharmacy Bulk Package Vials. We continue to strengthen our commitment to bring quality and affordable alternatives to market for patients in need with each injectable launch.”

<sup>1</sup>Glenmark's Potassium Phosphates Injection USP, 15 mmol P / 22 mEq K per 5 mL and 45 mmol P / 66 mEq K per 15 mL Single-Dose Vials and 150 mmol P / 220 mEq K per 50 mL Pharmacy Bulk Package Vials is only approved for the indication(s) listed in Glenmark's approved label.

<sup>2</sup>Market includes brand and all available therapeutic equivalents. Note: IQVIA® data obtained by Glenmark is only available for all approved RLD indications. Glenmark's product is only approved for the indications listed in Glenmark's approved label and is not marketed for all RLD indications.

\*IQVIA® National Sales Perspectives: Retail & Non-Retail, January 2026

## About Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is a global, research-led pharmaceutical company with a unique focus on innovation and accessibility. We pioneer transformative breakthrough therapies that aim to redefine treatment while expanding access to high-quality and affordable medicines for patients around the world. With 11 world-class manufacturing facilities across four continents, supported by six cutting-edge R&D centres, and a commercial footprint in 80+ countries, we deliver a diversified portfolio across branded, innovative, generics, and consumer health products, with a focus on respiratory, dermatology, and oncology. Scrip 100 positions Glenmark among the Top 100 biopharmaceutical companies globally by pharmaceutical sales for 2024. For more information, visit [www.glenmarkpharma.com](http://www.glenmarkpharma.com)

## For more information, please contact :

In the U.S.:	In India:
<p>Akhila Natarajan <a href="mailto:mediarelations@glenmarkpharma.com">mediarelations@glenmarkpharma.com</a> +91 98216 89525</p> <p>Danielle Hagen, Nahigian Strategies <a href="mailto:danielle@nahigianstrategies.com">danielle@nahigianstrategies.com</a> 202-365-6112</p>	<p>Akhila Natarajan <a href="mailto:mediarelations@glenmarkpharma.com">mediarelations@glenmarkpharma.com</a> +91 98216 89525</p> <p>Adfactors PR <a href="mailto:glenmark@adfactorspr.com">glenmark@adfactorspr.com</a> +91 88502 91322</p>